alexa Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents.


Surgery: Current Research

Author(s): Sticca RP, Dach BW

Abstract Share this page

Abstract Hyperthermia is selectively cytotoxic for malignant cells due to inhibition of oxidative metabolism causing lower pH in the microenvironment of the malignant cells and tumor. The increased acidity increases lysosymal activity and subsequent cell death. Hyperthermia alone as a primary treatment modality for malignancy has largely been abandoned due to high morbidity and mortality and high recurrence rates. Advances in administration and monitoring of hyperthermia, especially for regional applications, has allowed for the use of hyperthemia in conjunction with other modalities of antineoplastic therapy. Hyperthermia has been shown to potentiate chemotherapy and radiation by several different mechanisms. HIIC uses the advantages of hyperthermia in conjunction with chemotherapy for the management of peritoneal carcinomatosis. Several different chemotherapy agents have been shown to have improved therapeutic index and efficacy when used with hyperthermia in the management of peritoneal carcinomatosis.
This article was published in Surg Oncol Clin N Am and referenced in Surgery: Current Research

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

  • Rheumatology and Arthritis Surgeons Meeting
    October 2-4, 2017 Las Vegas , USA
  • 3rd International Conference on Spinal Surgery
    October 16-18, 2017, Chicago, USA
  • Global surgeons meeting on Bariatric surgery
    October 30-November 1, 2017,San Antonio,USA

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version